When a Healthcare Giant Gets Sick: Elevance Health's 20% YTD Decline

Elevance Health (ELV) shares have declined 20.3% year-to-date, significantly underperforming peers, as the company faces substantial headwinds including a 15.1% reduction in Medicaid membership in 2024, rising medical costs, and a worsening benefit expense ratio. Management subsequently cut its 2025 adjusted EPS outlook to approximately $30 from a prior range of $34.15-$34.85, leading to widespread analyst downgrades and a 'Strong Sell' rating. While ELV's valuation is now significantly discounted at 9.24x forward P/E and it possesses long-term growth drivers like product expansion and share repurchases, the immediate outlook remains clouded by ongoing membership pressures, cost inflation, and regulatory uncertainty, advising caution for investors.

Analysis

Elevance Health (ELV) is facing significant fundamental pressure, reflected in its 20.3% year-to-date stock price decline. The core issues are twofold: contracting revenue streams and compressing margins. Membership is shrinking, most notably in the Medicaid business which saw a 15.1% decline in 2024 followed by another 4.1% in the first half of 2025. Simultaneously, the benefit expense ratio deteriorated by 260 basis points year-over-year to 88.9% in the second quarter, with a full-year forecast of approximately 90%, indicating rising medical costs are outpacing premiums. This operational strain forced management to cut its full-year 2025 adjusted EPS guidance to approximately $30, a material reduction from the previous range of $34.15-$34.85 and below the 2024 reported figure of $33.04. The negative outlook is reinforced by widespread analyst downgrades and a Zacks Rank #5 (Strong Sell). While the company's valuation appears discounted at a 9.24x forward P/E and it maintains strong capital return policies, including a 2.33% dividend yield and an $8 billion buyback authorization, these long-term positives are currently overshadowed by severe near-term operational and regulatory headwinds, including potential legislative changes to Medicaid and scrutiny of its PBM business.

Key Decisions for Investors

• Given the significant downward revision in EPS guidance, shrinking membership, and rising cost pressures, investors should exercise caution as the stock's low valuation may represent a value trap in the near term.
• For long-term investors attracted by the discounted valuation, focus should be on the company's capital allocation efficiency, particularly the execution of its $8 billion share repurchase program, which could provide a floor for the stock.
• Monitor upcoming quarterly reports for any stabilization in the benefit expense ratio and Medicaid membership figures, as a positive inflection in these key metrics would be the first sign of a potential turnaround.
• Investors must closely track legislative and regulatory news flow related to Medicaid funding and Pharmacy Benefit Manager (PBM) reforms, as these factors represent significant external risks to the company's earnings power.